HIGH

Teva Isotretinoin 40 mg Capsules Recalled for Superpotent and Subpotent Lots (D-0446-2026)

Teva Pharmaceuticals USA, Inc. recalls 8,376 isotretinoin 40 mg capsules distributed to FL, OH, PR and MS after FDA enforcement report flags superpotent and subpotent lots. Patients should stop use and contact their healthcare providers for guidance.

Quick Facts at a Glance

Recall Date
January 12, 2026
Hazard Level
HIGH
Brands
Isotretinoin, Teva Pharmaceuticals USA, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
4 states
At-Risk Groups
GENERAL, PREGNANT, PETS

Hazard Information

Superpotent and Subpotent

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Isotretinoin is a prescription retinoid used for severe acne. It requires strict medical supervision.

Why This Is Dangerous

Potency variance means dose accuracy can be affected, potentially reducing efficacy or increasing adverse effects.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

No injuries reported yet; patients may experience variable treatment response if potency differs.

Practical Guidance

How to identify if yours is affected

  1. Check the carton NDC 0591-2436-15.
  2. Check blister NDC 0591-2436-45.
  3. Review lot numbers: 100075305, 100075512, 100076103, other lots with Exp 06/2027 or 07/2027.

Where to find product info

Recall page and FDA enforcement notice; packaging labels show NDCs and lot numbers.

What timeline to expect

Refunds or replacements will be communicated by mail letter; processing timelines not specified.

If the manufacturer is unresponsive

  • Document contact attempts.
  • Escalate to consumer protection agencies if no response.
  • Consult your healthcare provider for interim guidance.

How to prevent similar issues

  • Verify lot numbers and expiration dates before dispensing.
  • Maintain updated patient records with lot tracking.
  • Ask pharmacies to verify potency and lot integrity on dispensing.

Documentation advice

Keep recall notification, packaging, and any medical records related to isotretinoin treatment.

Product Details

Product: Isotretinoin Capsules, USP, 40 mg, 10 count Prescription Pacs. Manufacturer: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. NDC: 0591-2436-15 (carton), 0591-2436-45 (blister). Classification: Class II. Recall number: D-0446-2026. Quantity: 8,376 packages. Distribution: Florida, Ohio, Puerto Rico, Mississippi.

Reported Incidents

No specific injuries or adverse events are reported in the provided data.

Key Facts

  • 8,376 packages recalled
  • Lots: 100075305 with Exp date 06/2027; 100075512; 100076103 with Exp date 07/2027; other references:
  • Exp dates July 2027 for multiple lots
  • NDCs: 0591-2436-15 (carton), 0591-2436-45 (blister)

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPETS
Injury Types
OTHER

Product Details

Model Numbers
Lot 100075305 Exp 06/2027
Lot 100075512
Lot 100076103 Exp 07/2027
Lot with Exp 07/2027
UPC Codes
0591-2433
0591-2434
0591-2451
+13 more
Affected States
FL, OH, PR, MS
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more